Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 1, 2001, Pages 1-14

  Askanas, Valerie ^a,b   Engel, W KING ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Aging; Alzheimer disease; Amyloid ; Inclusion body myositis; Paired helical filaments; Phosphorylated tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; RNA; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ELECTRON MICROSCOPY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; INCLUSION BODY MYOSITIS; MYOFILAMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION;

EID: 0035145398     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.1.1     Document Type: Review

References (72)

1. Inclusion body myositis
2. Amyloid filaments in inclusion body myositis
3. Light- and electronmicroscopic localization of β-amyloid protein in muscle biopsies of patients with inclusion-body myositis
4. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging
5. New advances in inclusion-body myositis
6. Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular-pathologic similarities to Alzheimer disease
7. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: Current concepts of diagnosis and pathogensis
8. Inclusion body myositis
9. Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms. Personal experience
10. Evaluation of treatment for sporadic inclusion-body myositis
11. Rapid examination of muscle tissue and improved trichrome method for fresh-frozen biopsy sections
12. Enhanced detection of congored positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique
13. Use of antineurofilament antibody to identify paired-helical filaments in inclusionbody myositis
14. Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles
15. Immunocytochemical localization of ubiquitin in inclusion-body myositis allows its light-microscopic distinction from polymyositis
16. Ubiquitin immunostaining and inclusion body myositis: Study of 30 patients with inclusion body myositis
17. Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau
18. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies
19. β-amyloid precursor epitopes in muscle fibers of inclusion-body myositis
20. The genetics of the amyloidoses
21. Alzheimer's disease. Initial report of the purification and characteristics of a novel cerebrovascular amyloid protein
22. Isolation of low molecular weight proteins from amyloid plaque fibers in Alzheimer's disease
23. Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles
24. Neuropathology of synuclein aggregates: New insights into mechanisms of neurodegenerative diseases
25. Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins
26. Partial expression in oculopharyngeal muscular dystrophy (OPMD) muscle fibers of the intracellular phenotype of sporadic inclusion-body myositis (s-IBM)
27. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease
28. The molecular and genetic basis of AD: The end of the beginning. The 2000 Wartenberg lecture
29. β-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle
30. Possible pathogenic role of redox factor-1 and the AP-1 transcription factor components in sporadic inclusion-body myositis (s-IBM)
31. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2
32. Tan as a marker for Alzheimer's disease
33. Advanced maillard reaction end products are associated with Alzheimer disease pathology
34. Association of active extracellular signal-regulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation
35. Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation
36. Inclusion-body myositis, phosphorylated tau and tan kinases
37. Abberant expression of cyclin-dependent kinase 5 in inclusion body myositis
38. The muscle mitogen-activated protein kinase is altered in sporadic inclusion body myositis
39. Does dysregulation of the notch and wingless/Wnt pathways underlie the pathogenesis of Atzheimer's disease
40. mark)
41. RNA stimulates aggregation of microtubule-associated protein tan into Alzheimer-like paired helical filaments
42. Paired helical filaments of inclusion-body myositis muscle contain RNA and survival motor neuron protein
43. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion-body myositis and myopathies
44. Light and electron microscopic immunolocalization of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy
45. Prion protein is strongly immunolocalized at the pcstsynaptic domain of human normal neuromuscular junctions
46. Abnormal accumulation of priori protein mRNA in muscle fibers of patients with sporadic inclusionbody myositis and hereditary inclusion-body myopathy
47. Prion protein is abnormally accumulated in inclusion-body myositis
48. Human prion diseases
49. Novel immunolocalization of α-synuclein in human muscle of inclusion-body myositis, regenerating and necroric muscle fibers, and at neuromuscular junctions
50. αB-Crystallin immunolocalization yields new insights into inclusion body myositis
51. The molecular chaperone αB-crystallin enhances amyloid β Neurotoxicity
52. A direct role for protein kinase c and the transcription factor Jun/AP-I in the regulation of the Alzheimer's β-amyloid precursor protein gene
53. AP-1 function and regulation
54. New insights into the regulation of protein kinase C and novel phorbol ester receptors
55. Redox factor-1 in muscle biopsies of patients with inclusion-body
56. Immunolocalization of transcription factor NF-κB in inclusion-body myositis muscle and at normal human neuromuscular junctions
57. Expression of RNA polymerase II and its colocalization with phosphorylated tau in abnormal muscle fibers of sporadic inclusion-body myositis (s-IBM)
58. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis
59. Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy
60. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex
61. Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile Allele
62. Cultured muscle fibers from Iranian Jewish patients with quadriceps-sparing autosomal-recessive inclusion-body myopathy (AR1-IBM) express features of IBM phenotype
63. Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: Relevance to inclusion-body myopathies
64. Ultrastructural abnormalities of neuromuscular junctions in sporadic inclusion-body myositis
65. The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis
66. Does overexpression of βAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's Disease
67. Alzheimer's disease: A re-examination of the amyloid hypothesis
68. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Diseases of oxidative stress and aging?
69. Viruses, immunodeficiency, and inclusion-body myositis
70. Expression of human IAP-like protein in skeletal muscle A possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies
71. Fourteen newly recognized proteins at the human neuromuscular junctions - And their nonjunctional accumulation in inclusion-body myositis
72. The Alzheimer family of diseases: Many etiologies, one pathogenesis?